Exploring the Safety & Efficacy Profile of ABBV-400 in CRC to Assess ADC Impact in Unmet Solid Tumor Medical Need - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Exploring the Safety & Efficacy Profile of ABBV-400 in CRC to Assess ADC Impact in Unmet Solid Tumor Medical Need

12:00 pm - Tuesday 13th October 2026

Laying out the history and progress made developing ADCs and other therapeutics against c-Met
Detailing the safety and efficacy profile of ABBV-400, focused on CRC and solid tumor indications
Exploring future development plans and potential of ABBV 400 in impact CRC patients currently underserved by ADC therapies

Speakers:

Hua Fang

Hua Fang

Scientific Director - Oncology Clinical Development

Abbvie